NervGen Pharma Appoints John Ruffolo to Board of Directors
Extensive experience in private equity, venture capital and advising high growth, innovative companies Brings personal experience and knowledge of spinal cord injury to NervGen’s board Important board addition joins as Company advances clinical milestone with Phase 1b/2a study of NVG-291 underway Vancouver, Canada, October 17, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage […]
NervGen Pharma Grants Stock Options
Vancouver, British Columbia–(Newsfile Corp. – May 31, 2022) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 180,000 incentive stock options to a director exercisable at a price of $2.08 per share for […]
NervGen Hosting Panel Discussion with Leading Experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)
Panel discussion will focus on the successful translation of NervGen’s lead compound, NVG-291, from animals to humans Leading spinal cord injury experts on the panel include Drs. Jerry Silver, Monica Perez and James Guest NervGen will also present at the International Investment Forum Vancouver, Canada. May 16, 2022 – NervGen Pharma Corp. (TSX-V: NGEN; […]
NervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results
Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No serious or severe adverse events reported in second dose cohort with NVG-291 Successful completion of the second cohort establishes a clear pathway to selecting a dose for upcoming Phase 1b/2 clinical trials Vancouver, Canada. […]
NervGen Pharma Responds To Recent Increase In Market Activity
Vancouver, Canada. January 13, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, confirms that the Company’s management is unaware of any undisclosed information or material change in the Company’s operations that would account for the […]
NervGen Pharma Appoints Paul Brennan As President & Chief Executive Officer / Lloyd Mackenzie Appointed to The New Position of Chief Operating Officer
Vancouver, Canada. November 27, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Mr. Paul Brennan to the position of President & CEO effective immediately, replacing Dr. Ernest Wong who will […]
NervGen Pharma Completes Share Issuance to Drug Manufacturing Partner CSBio
Vancouver, Canada. November 21, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that, further to its press release dated November 18, 2019, it has issued 1,500,000 common shares (the “Common Share(s)”) to its […]
NervGen Pharma Receives Investment from Drug Manufacturing Partner / CSBio Invests US$1,500,000 As Part of Manufacturing Contract For Clinical Trial Product
Vancouver, Canada. November 18, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has entered into an agreement to issue 1,500,000 common shares at a price of US$1.00 (CA$1.3231 equivalent) per common […]
NervGen Pharma Expands Platform Into Alzheimer’s Disease / NervGen Pharma’s NVG-291 Compound on Track to Begin Phase 1 in Q1 2020
Vancouver, Canada. October 28, 2019 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a regenerative medicine company dedicated to creating novel treatments for nerve damage and neurodegenerative diseases, today announced a research initiative to advance its proprietary therapeutic technology platform, currently in development for spinal cord injury and multiple sclerosis, to […]